EpiCypher Announces Next-Generation Histone Peptide Array

EpiTitan™ to replace first-generation EpiGold™ Array

Chapel Hill, N.C. – August 25, 2014 – EpiCypher, a pioneer in the field of epigenetics and chromatin biology, announced today the introduction of its next-generation Histone Peptide Array – EpiTitan™. The platform was designed for rapid, high-throughput screening of effector protein interaction, antibody binding and enzyme activity. The peptides on the array encompass over 95 unique modifications on the four core histones along with several histone variants – the most available of any platform on the market.

“EpiTitan is a significant improvement over our previous platform,” said Jim Bone, President and co-founder of EpiCypher. “Some of the improvements include the capability to perform multiple experiments per array, 20 additional peptides, the ability to run two samples on one array, a significantly increased number of modifications, as well as enhanced scanning and analysis tools. This new platform will provide our customers with conclusions at critical phases of research with significantly reduced errors arising from other peptide array platforms. It also includes our patent-pending peptide spotting tracer, which significantly increases the believability of the data by reducing false negatives”.

About EpiCypher Pioneering the Science of Epigenetics™. A pioneer in the field of epigenetics and chromatin biology, EpiCypher is a bioscience company developing transformative technologies and delivering superior products to researchers world-wide. EpiCypher’s patented EpiTitan™ Histone Peptide Array is the most advanced histone array currently available. EpiCypher also sells purified and recombinant nucleosomes, recombinant histone binding proteins, peptides and antibodies, as well as peptide synthesis and peptide array screening services. For more information about EpiCypher, visit epicypher.com.

Media Contact: Leslie Lewis, EpiCypher, Inc. [email protected]